Leg­end scraps tri­al of its fol­low-up au­tol­o­gous CAR-T weeks af­ter clin­i­cal hold was lift­ed

Six weeks af­ter get­ting its clin­i­cal hold lift­ed, Leg­end Biotech has de­cid­ed to ter­mi­nate the Phase I study of its CAR-T tar­get­ing CD4+.

The news was tucked in­to an SEC fil­ing, and Leg­end con­firmed to End­points News in an email that the US study of LB1901 was scrapped, as well as a sep­a­rate in­ves­ti­ga­tor-ini­ti­at­ed Phase I study in Chi­na of a sim­i­lar prod­uct (LCAR-T2C) us­ing the same CAR pro­tein.

On­ly one pa­tient had been en­rolled in Leg­end’s Phase I study and the biotech nev­er re­sumed the tri­al af­ter the Feb­ru­ary clin­i­cal hold was lift­ed in late-May, a com­pa­ny spokesper­son told End­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER